Yuval Cohen
Net Worth

Last updated:

What is Yuval Cohen net worth?

The estimated net worth of Dr. Yuval Cohen is at least $9,997,360 as of 26 Jan 2024. He owns shares worth $896,840 as insider and has received compensation worth at least $9,100,520 in Corbus Pharmaceuticals Holdings, Inc..

What is the salary of Yuval Cohen?

Dr. Yuval Cohen salary is $827,320 per year as Chief Executive Officer & Director in Corbus Pharmaceuticals Holdings, Inc..

How old is Yuval Cohen?

Dr. Yuval Cohen is 50 years old, born in 1975.

What stocks does Yuval Cohen currently own?

As insider, Dr. Yuval Cohen owns shares in one company:

Company Title Shares Price per share Total value
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Chief Executive Officer & Director 98,230 $9.13 $896,840

What does Corbus Pharmaceuticals Holdings, Inc. do?

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

CRBP logo
CRBP
Corbus Pharmaceuticals Holdings, Inc.
$9.13

Yuval Cohen insider trading

Corbus Pharmaceuticals Holdings, Inc.

Transaction Date Security Shares Price per share Total value Source
Option
Options to purchase common stock 7,179 $4.97 $35,680
Option
Common Stock 7,179 $4.97 $35,680
Purchase
Common Stock 3,800 $0.26 $1,003
Purchase
Common Stock 10,500 $0.25 $2,625
Purchase
Common Stock 8,600 $0.37 $3,182
Purchase
Common Stock 4,240 $1.21 $5,126
Purchase
Common Stock 4,300 $3.49 $15,007
Purchase
Common Stock 1,430 $4.26 $6,092
Purchase
Common Stock 1,175 $6.06 $7,116
Purchase
Common Stock 995 $6.99 $6,955
Purchase
Common Stock 1,530 $6.49 $9,930
Purchase
Common Stock 1,725 $5.85 $10,091
Purchase
Common Stock 1,160 $6.89 $7,987
Purchase
Common Stock 1,000 $7.17 $7,169
Purchase
Common Stock 1,695 $6 $10,170
Purchase
Common Stock 3,250 $6.01 $19,539
Option
Common Stock 20,000 $1 $20,000
Option
Options to purchase common stock 20,000 $1 $20,000
Purchase
Common Stock 2,680 $7.64 $20,475
Option
Common Stock 20,000 $1 $20,000
Option
Options to purchase common stock 20,000 $1 $20,000
Purchase
Common Stock 1,500 $3.34 $5,010
Purchase
Common Stock 2,125 $2.4 $5,100
Purchase
Common Stock 535 $1.76 $941
Purchase
Common Stock 850 $1.73 $1,471
Purchase
Common Stock 550 $1.95 $1,070
Purchase
Common Stock 2,100 $1.92 $4,030
Purchase
Common Stock 900 $3.28 $2,952
Purchase
Common Stock 400 $3.66 $1,464
Purchase
Common Stock 500 $3.3 $1,650
Purchase
Common Stock 1,000 $3.2 $3,200